Novavax sets back COVID-19 vaccine FDA authorization request to fourth quarter

www.foxbusiness.com
2 min read
fairly difficult
Maryland-based biotech Novavax announced a delay in plans to file for U.S. FDA authorization of its COVID-19 vaccine.
Maryland-based biotech Novavax announced a delay in plans to file for U.S. FDA authorization of its COVID-19 vaccine last week. The company said it intends to file for emergency approval in the fourth quarter.

Novavax also announced it asked regulators in India, Indonesia and the Philippines to allow emergency use of its COVID-19 vaccine -- offering its shot to some low-income countries before rich ones with ample supplies. The company partnered with the Serum Institute of India to apply in the three countries.

MORE SMALL BUSINESSES WEIGHING VACCINE MANDATES FOR EMPLOYEES AS DELTA VARIANT SPREADS

Preliminary company findings suggested a single booster dose administered six months after the initial two-dose regimen resulted in a 4.6-fold increase in antibody levels, with an over 6-fold…
Kayla Rivas
Read full article